As shown in Fig. 4A and C, mice treated with cisplatin followed by CpG and PADRE generated the highest percentage of PADRE-specific CD4+ T cells among tumor-infiltrating CD4+ T cells compared to all other treatment groups. Here, CD4 is linked to neoplasm.